Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 15/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 13/20 | 0.56 |
| ▸ | EGFR | P00533 | 13/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.56 |
| ▸ | PRKDC | P78527 | 12/20 | 0.56 |
| ▸ | ABL1 | P00519 | 11/20 | 0.56 |
| ▸ | HCK | P08631 | 11/20 | 0.56 |
| ▸ | KDR | P35968 | 11/20 | 0.56 |
| ▸ | MTOR | P42345 | 11/20 | 0.56 |
| ▸ | EPHB4 | P54760 | 11/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 7/20 | 0.54 |
| ▸ | IGF1R | P08069 | 3/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butyl Formate SCHEMBL27733969 | 0.92 | SRC (0.53) | SRCPIK3CDEGFRPIK3CAPIK3CB | |
| SCHEMBL2959431 | 0.91 | EGFR (0.56) | SRCPIK3CDEGFRPIK3CAPIK3CB | |
| SCHEMBL2962222 | 0.91 | EGFR (0.56) | SRCPIK3CDEGFRPIK3CAPIK3CB | |
| SCHEMBL4977239 | 0.90 | SRC (0.49) | SRCPIK3CDEGFRPIK3CAPIK3CB | |
| SCHEMBL16762572 | 0.90 | SRC (0.49) | SRCPIK3CDEGFRPIK3CAPIK3CB | |
| SCHEMBL2961978 | 0.90 | SRC (0.59) | SRCPIK3CDEGFRPIK3CAPIK3CB | |
| SCHEMBL2960030 | 0.89 | IGF1R (0.57) | SRCPIK3CDEGFRPIK3CAPIK3CB | |
| SCHEMBL4979594 | 0.89 | SRC (0.48) | SRCPIK3CDEGFRPIK3CAPIK3CB | |
| SCHEMBL2959607 | 0.87 | IGF1R (0.54) | SRCPIK3CDEGFRPIK3CAPIK3CB | |
| SCHEMBL2956130 | 0.87 | IGF1R (0.54) | SRCPIK3CDEGFRPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973917-B1 | PROTEIN KINASE INHIBITORS | ABBVIE INC (US) | 2015-06-10 | — | — | EP | disclosed |
| US-7772231-B2 | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2010-08-10 | — | — | US | disclosed |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | ABBVIE INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | PACSIN2, MAP3K20, PHKG1 | SRC 106/4885PIK3CD 264/4885EGFR 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.